journal article·2025-12Open access

Dual-functional pH-sensitive nanoliposomes modified with CD47 mimicry peptide enhance icariin delivery to attenuate neuroinflammation and oxidative stress in epilepsy

Jing Wang, Yangsa Du, Guoting Su, Weiting Tang, Xiaoyan Long, Yongju He, Li Feng

Abstract

Around 30 % of patients fail to achieve seizure-free with existing anti-seizure medications (ASMs), and developing drugs that target neuroinflammatory and oxidative stress may benefit patients with refractory epilepsy. The bioactive compound icariin (ICA) isolated from the traditional Chinese medicine Epimedium has strong anti-inflammatory and antioxidant effects. Nonetheless, the clinical application of ICA is restricted by its low bioavailability and limited ability to penetrate the blood-brain barrier (BBB). This research developed a pH-sensitive nanoliposome delivery system modified with CD47 mimicry peptide(ICA@LipD-CD47) to enhance the therapeutic efficacy of ICA for epilepsy. Through the immune escape mechanism of CD47 mimicry peptide, the phagocytosis of the drug-loaded nanoparticles by macrophages could be reduced, thereby facilitating the prolonged circulation of ICA. Additionally, considering the acidic microenvironment present in the epileptogenic foci, pH-sensitive liposomes could enhance the efficiency of ICA's targeted entry into the epileptogenic foci. In this study, network pharmacology, animal experiments, and transcriptomics analysis confirmed the effect of ICA in alleviating epilepsy-induced inflammation and oxidative stress. Moreover, ICA@LipD-CD47 demonstrated prolonged circulation and effective targeting of epileptogenic foci, significantly alleviating neuronal damage and cognitive dysfunction in epileptic mice. As a novel nano-delivery system, ICA@LipD-CD47 presents a promising approach to improve the therapeutic effectiveness of ICA for treating epilepsy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Medicinal Plant Pharmacodynamics Research · Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (54)

Show source-provided references
1. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies10.1212/WNL.0000000000003509 ↗
3. Incidence and prevalence of drug-resistant epilepsy: a systematic review and meta-analysis10.1212/WNL.0000000000011839 ↗
4. Anti-seizure medications: challenges and opportunities10.2174/0118715273275793231030060833 ↗
5. Recent advances in pharmacotherapy for epilepsy10.1097/WCO.0000000000001144 ↗
6. Neuroinflammation and epilepsy: from pathophysiology to therapies based on repurposing drugs10.3390/ijms25084161 ↗
7. Metabolic dysfunction and oxidative stress in epilepsy10.3390/ijms18112365 ↗
8. Progress report on new antiepileptic drugs: a summary of the eleventh eilat conference (EILAT XI)10.1016/j.eplepsyres.2012.10.001 ↗
9. Minocycline as potent anticonvulsant in a patient with astrocytoma and drug resistant epilepsy10.1016/j.seizure.2011.12.009 ↗
10. Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy10.1038/s41582-019-0217-x ↗
11. Icariin, an up-and-coming bioactive compound against neurological diseases: network pharmacology-based study and literature review10.2147/DDDT.S310686 ↗
12. The blood-brain barrier: structure, regulation, and drug delivery10.1038/s41392-023-01481-w ↗
13. An outline for the pharmacological effect of icariin in the nervous system10.1016/j.ejphar.2018.10.006 ↗
14. HPLC analysis and pharmacokinetics of icariin in rats10.1002/jssc.200600313 ↗
15. Recent advances in human iPSC-derived models of the blood-brain barrier10.1186/s12987-020-00191-7 ↗
16. Interplay between liposomes and IgM: principles, challenges, and opportunities
17. Liposomes as versatile agents for the management of traumatic and nontraumatic central nervous system disorders: drug stability, targeting efficiency, and safety10.4103/NRR.NRR-D-24-00048 ↗
18. Liposome and immune system interplay: challenges and potentials10.1016/j.jconrel.2019.05.030 ↗
19. pH-Responsive polyethylene glycol engagers for enhanced brain delivery of PEGylated nanomedicine to treat glioblastoma10.1021/acsnano.4c05906 ↗
20. Liposomal drug delivery: a versatile platform for challenging clinical applications
21. Functions and molecular mechanisms of the CD47-SIRPalpha signalling pathway10.1016/j.tcb.2008.12.001 ↗
22. Peptide-mediated inhibition of neutrophil transmigration by blocking CD47 interactions with signal regulatory protein alpha10.4049/jimmunol.172.4.2578 ↗
23. Harnessing CD47 mimicry to inhibit phagocytic clearance and enhance anti-tumor efficacy of nanoliposomal doxorubicin10.1080/17425247.2020.1772749 ↗
24. Large-scale animal model study uncovers altered brain pH and lactate levels as a transdiagnostic endophenotype of neuropsychiatric disorders involving cognitive impairment10.7554/eLife.89376.3 ↗
25. A stimuli-responsive combination therapy for recovering p53-inactivation associated drug resistance10.1016/j.msec.2019.110403 ↗
26. Tandem dual-ratiometric SERS probe enables raman imaging of neurological pH fluctuations in epilepsy
27. The pilocarpine model of epilepsy in mice10.1111/j.1528-1157.1996.tb00541.x ↗
28. Microvascular stabilization via blood-brain barrier regulation prevents seizure activity10.1038/s41467-022-29657-y ↗
29. Morris water maze: procedures for assessing spatial and related forms of learning and memory10.1038/nprot.2006.116 ↗
30. A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data10.1016/0166-4328(88)90157-X ↗
31. Novel object recognition test for the investigation of learning and memory in mice10.3791/55718 ↗
32. The novel object recognition memory: neurobiology, test procedure, and its modifications10.1007/s10339-011-0430-z ↗
33. Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes10.1016/S0928-0987(00)00123-8 ↗
34. Inflammation and reactive oxygen species as disease modifiers in epilepsy10.1016/j.neuropharm.2019.107742 ↗
35. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics10.3390/ijms22052719 ↗
36. The interleukin-1 family: back to the future10.1016/j.immuni.2013.11.010 ↗
37. Targeting Interleukin-6 signaling in clinic10.1016/j.immuni.2019.03.026 ↗
38. HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo10.1016/j.bcp.2020.113922 ↗
39. The IL-17 family of cytokines in health and disease10.1016/j.immuni.2019.03.021 ↗
40. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer10.1517/13543780903321490 ↗
41. A novel ketone-supplemented diet improves recognition memory and hippocampal mitochondrial efficiency in healthy adult mice10.3390/metabo12111019 ↗
42. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies10.1016/j.apsb.2020.11.023 ↗
43. Anti-inflammatory effects of icariin in the acute and chronic phases of the mouse pilocarpine model of epilepsy10.1016/j.ejphar.2023.176141 ↗
44. Bioactive Icariin/β-CD-IC/Bacterial cellulose with enhanced biomedical potential10.3390/nano11020387 ↗
45. Isolation, characterization and in vitro cytotoxicity studies of bioactive compounds from Alseodaphne semecarpifolia nees10.1016/j.heliyon.2021.e07325 ↗
46. Icariin delivery system based on covalent organic framework materials: dual effects of immune modulation and osteogenesis promotion10.1039/D5RA01207D ↗
47. Spectroscopic investigation of the interactions of cryptotanshinone and icariin with two serum albumins10.1007/s10953-013-0022-x ↗
48. Preparation and application of pH-responsive drug delivery systems10.1016/j.jconrel.2022.05.056 ↗
49. Less is more: biomimetic hybrid membrane nanocarriers for highly efficient tumor targeted drug delivery
50. Use of extended-release and immediate-release anti-seizure medications with a long half-life to improve adherence in epilepsy: a guide for clinicians10.1016/j.yebeh.2021.107993 ↗
51. Molecular and cellular mechanisms of pharmacoresistance in epilepsy10.1093/brain/awh682 ↗
52. In vivo imaging of neuroinflammatory targets in treatment-resistant epilepsy10.1007/s11910-020-1025-9 ↗
53. Microglia in epilepsy10.1016/j.nbd.2023.106249 ↗
54. Microglia signatures: a cause or consequence of microglia-related brain disorders?10.3390/ijms252010951 ↗